Obstructive Sleep Apnea in Adults: Relationship with Cardiovascular and Metabolic Disorders is a comprehensive medical text edited by Alain Lurie as part of the Advances in Cardiology series (Volume 46), published by S. Karger AG in 2011. The book examines the intricate links between obstructive sleep apnea (OSA) and a host of cardiovascular and metabolic conditions that affect millions of adults worldwide. It synthesizes clinical, pathophysiological, and epidemiological research to provide clinicians and scientists with a deep understanding of how OSA contributes to systemic disease processes.
What Is Obstructive Sleep Apnea?
Obstructive sleep apnea (OSA) is a prevalent sleep-related breathing disorder characterized by recurrent partial or complete collapse of the upper airway during sleep, leading to interrupted airflow (apneas and hypopneas), nocturnal hypoxia (low oxygen levels), and repeated arousals from sleep. These events fragment sleep architecture, impair oxygenation, and trigger physiological stress responses.
Patients with OSA commonly experience excessive daytime sleepiness, loud snoring, and disturbed sleep, and the severity of OSA is typically quantified by the Apnea–Hypopnea Index (AHI), which measures the number of apneic and hypopneic events per hour of sleep.
OSA is especially prevalent in adults with obesity, older age, male sex, and certain craniofacial characteristics, making it a major public health concern given the global rise in obesity and metabolic syndrome.
Pathophysiological Mechanisms Linking OSA to Cardiovascular and Metabolic Disorders
The central thrust of the book is how OSA contributes to cardiovascular and metabolic disease through multiple overlapping physiological pathways. These include:
1. Intermittent Hypoxia and Oxidative Stress
Repeated episodes of nocturnal hypoxia followed by reoxygenation act like ischemia–reperfusion events, generating reactive oxygen species (ROS). This oxidative stress promotes endothelial dysfunction, systemic inflammation, and vascular injury. These mechanisms accelerate atherosclerosis and impair normal vascular responses, making OSA an independent risk factor for cardiovascular disease.
2. Inflammation and Procoagulant States
OSA is associated with elevated inflammatory markers (e.g., C-reactive protein, cytokines) and alterations in coagulation pathways. This creates a prothrombotic state, increasing the risk for clot formation, which may underlie higher rates of myocardial infarction and stroke observed in patients with untreated OSA.
3. Autonomic Nervous System Dysfunction
Recurrent apneas trigger sympathetic nervous system activation, leading to elevated blood pressure, heart rate variability, and impaired cardiac autonomic control. Chronic sympathetic excitation contributes to sustained hypertension and increases cardiac workload, worsening heart disease outcomes.
4. Endothelial Dysfunction
Endothelial cells line blood vessels and regulate vascular tone, blood clotting, and inflammation. In OSA, intermittent hypoxia and oxidative stress damage endothelial function, reducing nitric oxide availability, impairing vasodilation, and fostering atherosclerotic plaque formation.
5. Metabolic Dysregulation
OSA is closely linked with insulin resistance, glucose intolerance, and dyslipidemia — features of the metabolic syndrome. The stress of intermittent hypoxia alters glucose metabolism and insulin sensitivity, promoting type 2 diabetes and related metabolic conditions. Obesity further exacerbates this cycle, as adiposity increases OSA severity and metabolic dysfunction.
Clinical Manifestations and Comorbid Conditions
The book covers how these pathophysiological processes translate into clinical disorders:
-
Hypertension: OSA significantly increases the risk of new-onset and resistant hypertension due to repetitive oxygen desaturations and sympathetic activation.
-
Coronary Artery Disease: OSA contributes to plaque instability and progression of coronary atherosclerosis.
-
Heart Failure and Arrhythmias: Repeated hypoxemia and intrathoracic pressure swings impair cardiac function and predispose to atrial fibrillation and other rhythm disturbances.
-
Stroke: OSA increases stroke risk through vascular damage, prothrombotic tendencies, and blood pressure variability.
-
Metabolic Syndrome: Intersections between OSA and metabolic disorders amplify cardiovascular risks, particularly in adults with obesity.
Diagnosis and Treatment
Diagnosis of OSA typically involves polysomnography (sleep studies) that quantify breathing disruptions and oxygen levels during sleep. Clinicians also consider risk factors like obesity, neck circumference, and patient symptoms.
Continuous Positive Airway Pressure (CPAP) therapy remains the gold standard for treating moderate to severe OSA. CPAP devices maintain airway patency during sleep, mitigating apneas, reducing nocturnal hypoxia, and improving daytime symptoms. Studies show that consistent CPAP use can:
-
Lower blood pressure
-
Improve endothelial function
-
Reduce markers of inflammation
-
Enhance metabolic profiles
However, the evidence on whether CPAP reduces long-term cardiovascular mortality is mixed, with ongoing research investigating which patient groups benefit most.
Conclusion
In summary, Obstructive Sleep Apnea in Adults: Relationship with Cardiovascular and Metabolic Disorders provides a thorough exploration of how OSA — once considered mainly a sleep disturbance — is deeply interconnected with systemic cardiovascular and metabolic disease. It emphasizes the need for clinicians across specialties to recognize and treat OSA not only to improve sleep quality but also to reduce the burden of hypertension, heart disease, diabetes, and other chronic conditions.
By integrating basic science with clinical implications, the book serves as an essential resource for clinicians and researchers aiming to understand and manage the broader health impacts of obstructive sleep apnea.
Reviews
There are no reviews yet